Consolidated Statements of Equity - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Preferred Shares	Common Shares	Additional Paid-In Capital	Additional Paid-In Capital Cumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive Income (Loss)	Distributions in Excess of Retained Earnings	Total Shareholders' Equity	Total Shareholders' Equity Cumulative Effect, Period of Adoption, Adjustment	Non-Controlling Interests
Beginning balance (in shares) at Dec. 31, 2020			20,400,000	130,673,300
Beginning balance at Dec. 31, 2020	$ 3,264,326	$ (113,099)	$ 204	$ 1,307	$ 4,169,870	$ (113,099)	$ (60,071)	$ (853,973)	$ 3,257,337	$ (113,099)	$ 6,989
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares, net of offering costs	(10)				(10)				(10)
Issuance of common shares for Board of Trustees compensation (in shares)				27,711
Issuance of common shares for Board of Trustees compensation	516			$ 1	515				516
Repurchase of common shares (in shares)				(38,310)
Repurchase of common shares	(720)			$ (1)	(719)				(720)
Share-based compensation (in shares)				150,216
Share-based compensation	3,628			$ 1	3,278				3,279		349
Distributions on common shares/units	(1,085)							(1,077)	(1,077)		(8)
Distributions on preferred shares	(8,139)							(8,139)	(8,139)		0
Purchases of capped calls in connection with convertible senior notes	(20,975)				(20,975)				(20,975)
Other comprehensive income (loss):
Change in fair value of derivative instruments	9,736						9,736		9,736
Amounts reclassified from other comprehensive income	6,418						6,418		6,418
Net income (loss)	(121,440)							(120,582)	(120,582)		(858)
Ending balance (in shares) at Mar. 31, 2021			20,400,000	130,812,917
Ending balance at Mar. 31, 2021	3,019,156		$ 204	$ 1,308	4,038,860		(43,917)	(983,771)	3,012,684		6,472
Beginning balance (in shares) at Dec. 31, 2021			29,600,000	130,813,750
Beginning balance at Dec. 31, 2021	3,163,905		$ 296	$ 1,308	4,268,042		(19,442)	(1,094,023)	3,156,181		7,724
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common shares for Board of Trustees compensation (in shares)				33,866
Issuance of common shares for Board of Trustees compensation	738			$ 1	737				738
Repurchase of common shares (in shares)				(49,787)
Repurchase of common shares	(1,113)			$ (1)	(1,112)				(1,113)
Share-based compensation (in shares)				106,470
Share-based compensation	2,354			$ 1	1,655				1,656		698
Distributions on common shares/units	(1,131)							(1,122)	(1,122)		(9)
Distributions on preferred shares	(11,344)							(11,344)	(11,344)
Other comprehensive income (loss):
Change in fair value of derivative instruments	27,367						27,160		27,160		207
Amounts reclassified from other comprehensive income	4,374						4,374		4,374
Net income (loss)	(100,216)							(99,530)	(99,530)		(686)
Ending balance (in shares) at Mar. 31, 2022			29,600,000	130,904,299
Ending balance at Mar. 31, 2022	$ 3,084,934		$ 296	$ 1,309	$ 4,269,322		$ 12,092	$ (1,206,019)	$ 3,077,000		$ 7,934